CDK19抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse eye tissue lysate, Primary antibody: P04763(CDK19 Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 3 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P04763(CDK19 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P04763(CDK19 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

**Background of CDK19 Antibody**

Cyclin-dependent kinase 19 (CDK19) is a member of the CDK family, which plays critical roles in regulating transcription and cell cycle progression. It is a paralogue of CDK8. sharing structural similarities but exhibiting distinct functional roles. CDK19 associates with the Mediator complex, a multi-protein assembly that bridges transcription factors and RNA polymerase II, modulating gene expression. Unlike canonical CDKs involved in cell cycle control, CDK19 primarily influences transcriptional regulation, particularly in response to signaling pathways such as Wnt/β-catenin and hypoxia-inducible factors.

CDK19 antibodies are essential tools for studying its expression, localization, and interactions in cellular contexts. Dysregulation of CDK19 has been implicated in cancers (e.g., breast, prostate, colorectal), metabolic disorders, and neurological diseases, highlighting its potential as a therapeutic target. Antibodies targeting CDK19 enable researchers to investigate its isoform-specific functions, post-translational modifications, and roles in disease mechanisms. Therapeutic applications are emerging, with inhibitors and monoclonal antibodies being explored to disrupt CDK19-mediated oncogenic signaling.

Challenges in CDK19 research include its high homology with CDK8. necessitating highly specific antibodies to avoid cross-reactivity. Recent advances in structural biology and epitope mapping have improved antibody specificity, aiding both basic research and drug development. Ongoing studies aim to clarify CDK19's precise regulatory mechanisms and validate its utility in diagnostics and targeted therapies.